Radiation Therapy for Gynecological Cancer

A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Gynecologic Oncology".

Deadline for manuscript submissions: 30 September 2024 | Viewed by 589

Special Issue Editors


E-Mail Website
Guest Editor
Department of Oncology, University of Alberta, Edmonton, AB T6G 1Z2, Canada
Interests: gynecologic cancer; gynecologic brachytherapy; late effects; survivorship

E-Mail Website
Guest Editor
Department of Surgery, University of British Columbia, Vancouver, BC V5Z 4E6, Canada
Interests: gynecological malignancies; quality of life; patient reported outcomes; gynecologic brachytherapy

Special Issue Information

Dear Colleagues,

Radiation has been a mainstay in the definitive and adjuvant treatment of gynecologic cancers for decades. Over time, radiation treatment approaches for gynecologic cancers, treatment techniques, and technology have continually improved. Radiation treatment strategies that were previously based primarily on histological type, grade, and stage, are now being refined to incorporate clinical risk stratification, molecular/biomarker classification and treatment response; these risk-adapted approaches can inform escalation and de-escalation of treatment to improve outcomes. In addition, there have been advances in radiation techniques, including stereotactic ablative radiotherapy techniques and image-guided brachytherapy, that may further improve the toxicity profiles of radiation treatment.

Risk-adaption radiation approaches are exciting new opportunities to optimize the risk/benefit profile of treatment for gynecologic cancer. In this Special Issue of Current Oncology, we will present original research and review articles addressing the varied concepts of risk-adaption of radiation therapy in gynecologic cancer.

Dr. Ericka M. Wiebe
Dr. Iwa Kong
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gynecologic cancer
  • radiation therapy
  • risk adapted
  • molecular pathology
  • biomarkers

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 833 KiB  
Article
Adjuvant Treatment of Stage I–II Serous Endometrial Cancer: A Single Institution 20-Year Experience
by Aquila Akingbade, François Fabi, Rodrigo Cartes, James Tsui and Joanne Alfieri
Curr. Oncol. 2024, 31(7), 3758-3770; https://doi.org/10.3390/curroncol31070277 - 29 Jun 2024
Viewed by 333
Abstract
Background: Serous endometrial carcinoma (SEC) is a high-risk subtype of endometrial cancer. The effectiveness of multiple adjuvant therapies, namely chemotherapy (CT), radiotherapy (RT), and sequential/concurrent chemotherapy with radiotherapy (CRT), have previously been investigated. However, optimal management of early-stage SEC remains unclarified. Methods: All [...] Read more.
Background: Serous endometrial carcinoma (SEC) is a high-risk subtype of endometrial cancer. The effectiveness of multiple adjuvant therapies, namely chemotherapy (CT), radiotherapy (RT), and sequential/concurrent chemotherapy with radiotherapy (CRT), have previously been investigated. However, optimal management of early-stage SEC remains unclarified. Methods: All cases of early-stage SEC (FIGO 2009 stages I–II) treated in our institution from 2002 to 2019 were identified. Patient data were documented until September 2023. Overall survival (OS) and disease-free survival (DFS) were computed using Kaplan–Meier estimates and Cox’s proportional hazard model; descriptive statistical analysis was performed. Results: A total of 50 patients underwent total hysterectomy-bilateral salpingo-oophorectomy and omentectomy, displaying stage IA (60%), IB (24%), and II (16%) disease. The median follow-up was 90.9 months. Patients underwent adjuvant CRT (n = 36, 72%), CT (n = 6, 12%), or RT (n = 6, 12%). Two patients were observed and excluded from analyses. The 42 patients who received radiotherapy had pelvic external beam radiotherapy (n = 10), vaginal brachytherapy (n = 21), or both (n = 11). CRT had better OS (HR 0.14, 95%CI 0.04–0.52, p < 0.005) and DFS (HR 0.25, 95%CI 0.07–0.97, p = 0.05) than CT alone. RT displayed no OS or DFS benefits compared to CT/CRT. Recurrences were mostly distant. Acute and late G3-4 toxicities were primarily hematologic. Conclusions: Our data underline the challenge of treating SEC. CRT appears to be superior to CT alone but not to RT. Most recurrences were distant, highlighting the need for optimized systemic treatment options. Full article
(This article belongs to the Special Issue Radiation Therapy for Gynecological Cancer)
Show Figures

Figure 1

Back to TopTop